Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34461737 | 0.92 | TRPA1 (0.41) | TRPA1TGM2KDM4EMAPTTP53 | |
| SCHEMBL34461721 | 0.88 | TRPA1 (0.40) | TRPA1TGM2KDM4EMAPTTP53 | |
| SCHEMBL34461716 | 0.87 | TRPA1 (0.40) | TRPA1TGM2KDM4EMAPTTP53 | |
| SCHEMBL34461777 | 0.81 | ACHE (0.39) | KDM4EMAPTTP53 | |
| SCHEMBL34461766 | 0.80 | KDM4E (0.39) | TRPA1TGM2KDM4EMAPTTP53 | |
| SCHEMBL34461761 | 0.80 | TRPA1 (0.41) | TRPA1TGM2KDM4EMAPTAKR1B1 | |
| SCHEMBL34461758 | 0.79 | TRPA1 (0.45) | TRPA1KDM4EMAPTTP53AKR1B1 | |
| SCHEMBL34461722 | 0.76 | TRPA1 (0.43) | TRPA1KDM4EMAPTTP53AKR1B1 | |
| SCHEMBL34461756 | 0.76 | TRPA1 (0.39) | TRPA1TGM2KDM4EMAPTTP53 | |
| SCHEMBL34461730 | 0.76 | NPC1 (0.41) | KDM4EMAPTTP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2026-04-09 | — | — | US | claimed |
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2026-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | WRN, POLR1A, REV1 | TRPA1 3662/4885TGM2 4757/4885KDM4E 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.